Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2011

CDI to Supply iPSC-Derived Human Heart Cells for Roche's Drug Development Efforts

  • Cellular Dynamics International (CDI) and Roche report the completion of a two-year collaboration intended to substantiate the ability of CDI's iCell® Cardiomyocytes to assess potential cardiotoxic effects of drug candidates in development. The companies transitioned to a standard supply agreement under which iCell Cardiomyocytes will be incorporated into Roche's drug development decision-making process.

    "CDI and Roche have developed and demonstrated, respectively, a more efficient tool to reveal potential cardiotoxicity in their drug development candidates,” says Chris Parker, chief commercial officer of CDI. iCell Cardiomyocytes are produced from induced pluripotent stem cell (iPSC)-derived human heart cells.

    CDI and Roche initiated their collaboration in March 2009 to interrogate CDI's iCell Cardiomyocytes against a well-categorized compound reference set. The goal was to test the ability of the cardiomyocytes to predict drug-induced, potentially life-threatening cardiac arrhythmias.

    The studies included longitudinal genetic and molecular characterizations of the cardiomyocytes and assessment of their performance across a variety of testing platforms.  Multiple publications based on this research are being prepared for submission to peer-reviewed journals, the companies report.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »